PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS

Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LARSON, Ryan P, YEE, Nathan K, SUTHERLAND, Claire L, DEVRIES, Todd, RAMSBORG, Christopher Glen, HAUSE, Ronald James Jr, DAVE, Kedar Himanshu, YOST, Rachel K
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator LARSON, Ryan P
YEE, Nathan K
SUTHERLAND, Claire L
DEVRIES, Todd
RAMSBORG, Christopher Glen
HAUSE, Ronald James Jr
DAVE, Kedar Himanshu
YOST, Rachel K
description Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SG11202005217VA</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SG11202005217VA</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SG11202005217VA3</originalsourceid><addsrcrecordid>eNrjZDAP8HD18w-JDPB0VvB1DPJ2DQpWcPMPUnB29fFRCPFwDXIMiFRw9HNRCHL1cQxxdVHwdQ3x8HcJ5mFgTUvMKU7lhdLcDCpuriHOHrqpBfnxqcUFicmpeakl8cHuhoZGBkYGBqZGhuZhjsZEKgMAKywpkA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS</title><source>esp@cenet</source><creator>LARSON, Ryan P ; YEE, Nathan K ; SUTHERLAND, Claire L ; DEVRIES, Todd ; RAMSBORG, Christopher Glen ; HAUSE, Ronald James Jr ; DAVE, Kedar Himanshu ; YOST, Rachel K</creator><creatorcontrib>LARSON, Ryan P ; YEE, Nathan K ; SUTHERLAND, Claire L ; DEVRIES, Todd ; RAMSBORG, Christopher Glen ; HAUSE, Ronald James Jr ; DAVE, Kedar Himanshu ; YOST, Rachel K</creatorcontrib><description>Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20200729&amp;DB=EPODOC&amp;CC=SG&amp;NR=11202005217VA$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20200729&amp;DB=EPODOC&amp;CC=SG&amp;NR=11202005217VA$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LARSON, Ryan P</creatorcontrib><creatorcontrib>YEE, Nathan K</creatorcontrib><creatorcontrib>SUTHERLAND, Claire L</creatorcontrib><creatorcontrib>DEVRIES, Todd</creatorcontrib><creatorcontrib>RAMSBORG, Christopher Glen</creatorcontrib><creatorcontrib>HAUSE, Ronald James Jr</creatorcontrib><creatorcontrib>DAVE, Kedar Himanshu</creatorcontrib><creatorcontrib>YOST, Rachel K</creatorcontrib><title>PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS</title><description>Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAP8HD18w-JDPB0VvB1DPJ2DQpWcPMPUnB29fFRCPFwDXIMiFRw9HNRCHL1cQxxdVHwdQ3x8HcJ5mFgTUvMKU7lhdLcDCpuriHOHrqpBfnxqcUFicmpeakl8cHuhoZGBkYGBqZGhuZhjsZEKgMAKywpkA</recordid><startdate>20200729</startdate><enddate>20200729</enddate><creator>LARSON, Ryan P</creator><creator>YEE, Nathan K</creator><creator>SUTHERLAND, Claire L</creator><creator>DEVRIES, Todd</creator><creator>RAMSBORG, Christopher Glen</creator><creator>HAUSE, Ronald James Jr</creator><creator>DAVE, Kedar Himanshu</creator><creator>YOST, Rachel K</creator><scope>EVB</scope></search><sort><creationdate>20200729</creationdate><title>PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS</title><author>LARSON, Ryan P ; YEE, Nathan K ; SUTHERLAND, Claire L ; DEVRIES, Todd ; RAMSBORG, Christopher Glen ; HAUSE, Ronald James Jr ; DAVE, Kedar Himanshu ; YOST, Rachel K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SG11202005217VA3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2020</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>LARSON, Ryan P</creatorcontrib><creatorcontrib>YEE, Nathan K</creatorcontrib><creatorcontrib>SUTHERLAND, Claire L</creatorcontrib><creatorcontrib>DEVRIES, Todd</creatorcontrib><creatorcontrib>RAMSBORG, Christopher Glen</creatorcontrib><creatorcontrib>HAUSE, Ronald James Jr</creatorcontrib><creatorcontrib>DAVE, Kedar Himanshu</creatorcontrib><creatorcontrib>YOST, Rachel K</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LARSON, Ryan P</au><au>YEE, Nathan K</au><au>SUTHERLAND, Claire L</au><au>DEVRIES, Todd</au><au>RAMSBORG, Christopher Glen</au><au>HAUSE, Ronald James Jr</au><au>DAVE, Kedar Himanshu</au><au>YOST, Rachel K</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS</title><date>2020-07-29</date><risdate>2020</risdate><abstract>Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_SG11202005217VA
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
title PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T17%3A01%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LARSON,%20Ryan%20P&rft.date=2020-07-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESG11202005217VA%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true